Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DSG2-directed CAR-T cells
- Development stage
- Preclinical
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
DSG2-directed CAR-T cells are a type of chimeric antigen receptor T cell therapy targeting desmoglein 2 (DSG2), a cadherin protein. This investigational therapy is designed to target cells expressing DSG2, which modulates cell growth, survival, and metastasis. The therapy involves engineering a patient's own T cells to express a receptor that recognizes DSG2, potentially enabling them to identify and attack cells expressing this target.
02
Targets
DSG2 (Desmoglein-2)
Beyond the preview
Go deeper on DSG2-directed CAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DSG2-directed CAR-T cells.